Latest news with #Redox
Yahoo
26-05-2025
- Business
- Yahoo
Here's What's Concerning About Redox's (ASX:RDX) Returns On Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. In a perfect world, we'd like to see a company investing more capital into its business and ideally the returns earned from that capital are also increasing. This shows us that it's a compounding machine, able to continually reinvest its earnings back into the business and generate higher returns. So while Redox (ASX:RDX) has a high ROCE right now, lets see what we can decipher from how returns are changing. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. For those who don't know, ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business. The formula for this calculation on Redox is: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) 0.21 = AU$117m ÷ (AU$736m - AU$167m) (Based on the trailing twelve months to December 2024). Thus, Redox has an ROCE of 21%. In absolute terms that's a great return and it's even better than the Trade Distributors industry average of 12%. View our latest analysis for Redox In the above chart we have measured Redox's prior ROCE against its prior performance, but the future is arguably more important. If you're interested, you can view the analysts predictions in our free analyst report for Redox . On the surface, the trend of ROCE at Redox doesn't inspire confidence. To be more specific, while the ROCE is still high, it's fallen from 33% where it was five years ago. Meanwhile, the business is utilizing more capital but this hasn't moved the needle much in terms of sales in the past 12 months, so this could reflect longer term investments. It's worth keeping an eye on the company's earnings from here on to see if these investments do end up contributing to the bottom line. On a related note, Redox has decreased its current liabilities to 23% of total assets. That could partly explain why the ROCE has dropped. What's more, this can reduce some aspects of risk to the business because now the company's suppliers or short-term creditors are funding less of its operations. Since the business is basically funding more of its operations with it's own money, you could argue this has made the business less efficient at generating ROCE. In summary, Redox is reinvesting funds back into the business for growth but unfortunately it looks like sales haven't increased much just yet. Unsurprisingly then, the total return to shareholders over the last year has been flat. On the whole, we aren't too inspired by the underlying trends and we think there may be better chances of finding a multi-bagger elsewhere. Like most companies, Redox does come with some risks, and we've found 1 warning sign that you should be aware of. If you'd like to see other companies earning high returns, check out our free list of companies earning high returns with solid balance sheets here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
13-05-2025
- Health
- Yahoo
Creyos Partners with Redox to Eliminate Barriers to Cognitive Health Data in EHRs
Partnership redefines how health systems bring cognitive screening into routine care at scale TORONTO, May 13, 2025 /PRNewswire/ -- Creyos, the leading online platform for objective cognitive and behavioral health assessments, today announced its partnership with Redox, a leading provider of healthcare data interoperability solutions. This strategic collaboration enables large health systems and integrated delivery networks to seamlessly embed Creyos' cognitive testing into their electronic health records (EHRs), eliminating one of the biggest barriers to scaling proactive brain health care. This partnership comes at a time when cognitive and behavioral health assessments are becoming essential to high-quality, preventive care. Over 55 million people worldwide are currently living with dementia, and that number is projected to reach 139 million by 2050. Early and accurate screening is critical for enabling timely intervention, personalized care planning, and improved outcomes. As health systems shift toward value-based care, Creyos is helping providers make cognitive health a core part of routine care. Its tools are clinically proven and easy to implement. Most technology fails to gain traction in large health systems due to poor alignment with clinical workflows. Creyos overcomes this by leveraging Redox's expansive EHR network to deliver seamless data integration and platform access. Its scientifically validated dementia screening and assessments are now available at the point of care, right when providers need them. "We're at a turning point in how health systems approach cognitive health," said Marc Lipton, CEO of Creyos. "To deliver on the promise of value-based care, we need tools that don't just work clinically but also work operationally. This partnership with Redox eliminates the workflow and integration barriers that have slowed adoption for years. It puts Creyos assessments exactly where they need to be, within the systems clinicians already use." Redox's platform supports interoperability across more than 90 EHR systems including, Cerner, eClinicalWorks, and Allscripts, among many others. Health systems deploying Creyos through this partnership can automatically deliver cognitive assessments and patient results to their EHRs without complex, time-consuming IT work. This ensures: Timely Decision-Making: Providers receive screener and assessment data directly in their existing systems, allowing for faster clinical decision making, interventions, and coordinated care planning. Improved Clinical Workflow Efficiency: Automating the integration of cognitive test results reduces administrative burdens, giving providers more time to focus on patient care. Scalability for Large Health Systems: Whether supporting one location or a national network of clinics, the Creyos-Redox integration is highly scalable and adaptable to the unique needs of any enterprise system. Early Detection and Proactive Care: Cognitive health is a critical component of preventive care, especially in aging populations and for at-risk patient groups. By integrating Creyos' cognitive and behavioral assessments directly into EHRs, providers can monitor cognitive decline over time, ensuring they catch early warning signs of conditions such as dementia or mild cognitive impairment (MCI) before they worsen. "Creyos is bringing cognitive health into everyday clinical workflows, and we're proud to power that shift," said Trip Hofer, CEO of Redox. "When results from tools like this are embedded directly into EHR systems, providers can act sooner, and patients benefit from more timely, connected care. This is exactly the kind of integration we believe healthcare needs more of." Creyos EHR integration through Redox is now available for all Creyos customers. Health systems interested in getting Creyos for their practice can learn more by visiting About CreyosCreyos, formerly known as Cambridge Brain Sciences, is a pioneering healthcare technology company dedicated to transforming how healthcare providers assess and manage patient brain health. Supporting clinicians and health systems worldwide, the Creyos platform includes objective online tasks, digital behavioral health screeners, and condition-specific assessments that deliver actionable insights, promote early intervention, and enable evidence-based clinical decisions for various cognitive and behavioral health conditions, including dementia, ADHD, depression, anxiety, and others. Backed by 30 years of research and a normative database of over 85,000 participants, the FDA-registered Creyos platform has been published in over 400 peer reviewed studies and is recognized as a scientifically-validated solution for measuring and monitoring patient brain health. For more information about Creyos visit About RedoxRedox is your highway to better healthcare. We help providers, payers, digital health vendors/independent service providers, EHRs, and Life Sciences companies power better care with seamless data interoperability. Our secure platform's read/write capabilities translate, normalize, and enrich complex healthcare data in real time. With more than 9,600 live connections, organizations across North America use Redox technology to achieve faster speed to value across a wide range of systems, applications, and workflows. For more information, visit or follow us on LinkedIn and X. Media Contact: Erin SmithChief Marketing and Engagement Officer, Creyos(647)- View original content to download multimedia: SOURCE Creyos Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
06-05-2025
- Business
- Business Wire
IntelePeer and Redox Partner to Accelerate Implementation Timelines of AI Solutions for PE-backed Healthcare Companies
BUSINESS WIRE)--IntelePeer, the leading end-to-end conversational AI platform provider, and Redox, a leading provider of healthcare data interoperability solutions, today announce a new partnership to accelerate AI implementations for private equity-backed healthcare companies. Through this collaboration, healthcare groups using IntelePeer's SmartAgent and SmartOffice solutions can rely on the simplicity of a turnkey AI solution that can be rapidly deployed with secure access into hundreds of healthcare applications, including electronic health record (EHR) systems and Practice Management Solutions (PMS). Coupled with IntelePeer's reliable and scalable voice and omnichannel AI agents, these solutions enable organizations to achieve financial returns in less than three months. 'IntelePeer is deeply committed to helping private equity-backed healthcare organizations achieve tangible business results in less than 90 days,' said IntelePeer CEO, Frank Fawzi. 'By integrating Redox's industry-leading interoperability network with IntelePeer's AI-powered automation platform, we're eliminating one of the biggest pain points our healthcare customers face—connecting their communications systems within complex EHR and PMS environments. This integration allows providers to deploy communications solutions quickly and securely, all while maintaining compliance and improving business outcomes. It's a powerful step forward in enabling medical and dental practices to modernize operations, reduce administrative overhead, and rapidly deliver business results that increase revenue and improve net margins for their organizations.' Through the Redox partnership, IntelePeer is making it easy for healthcare organizations to streamline patient engagement, automate communications, and drive better outcomes through frictionless data exchange. Redox's secure and scalable platform allows IntelePeer to connect with more than 90 EHR systems, empowering organizations to: Increase revenue and drive greater efficiency and cost savings with improved appointment management, reduced no shows, and automated payment management. Improve care coordination by automating communications triggered by real-time EHR events. Reduce administrative burden with intelligent voice, SMS, and chatbot workflows that free up staff time. Enhance patient satisfaction and outcomes by meeting patients where they are with timely and relevant information. 'With Redox's real-time, bi-directional data exchange, IntelePeer customers can deliver personalized and connected experiences at the right time to improve patient care management and drive greater operational efficiencies,' said Rachel Witalec, Chief Product Officer at Redox. 'Dealing with disparate legacy data from multiple source formats is complex. Redox simplifies the process, delivering the necessary data in real-time to automate workflows and bring use cases to life, all while increasing in-office productivity.' IntelePeer's SmartAgent solution automates inbound interactions for medical practices and dental offices, helping them quickly and easily streamline front office responsibilities and empower self-service communications for a much faster ROI. It allows dental providers to manage spikes in call capacity and engage patients with conversational AI appointment management and reminders. This reduces front office or contact center costs while optimizing schedules and revenues and adhering to strict compliance measures. SmartOffice offers multi-facility practices, unparalleled automation, and enhanced interaction resolution. It allows for routine patient interactions to be addressed without the need for human intervention, giving staff time back to focus on more complex patient needs. To learn more about IntelePeer, visit: About IntelePeer IntelePeer streamlines customer interactions, enabling businesses and contact centers to lower costs, improve the customer experience, and accelerate return on investment. Harnessing the power of agentic AI, IntelePeer's Conversational AI Platform delivers speed, observability, visibility, and flexibility — all built on top of a global, secure communications network. Producing human-like interactions, the platform automates voice and digital customer service capabilities and provides industry-leading time-to-value with solutions that work seamlessly with existing enterprise software and infrastructure, and easy-to-use tools that can be utilized by anyone.
Yahoo
28-04-2025
- Business
- Yahoo
Are Redox Limited's (ASX:RDX) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
It is hard to get excited after looking at Redox's (ASX:RDX) recent performance, when its stock has declined 35% over the past three months. But if you pay close attention, you might find that its key financial indicators look quite decent, which could mean that the stock could potentially rise in the long-term given how markets usually reward more resilient long-term fundamentals. Particularly, we will be paying attention to Redox's ROE today. Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. Put another way, it reveals the company's success at turning shareholder investments into profits. We've discovered 1 warning sign about Redox. View them for free. The formula for return on equity is: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for Redox is: 17% = AU$91m ÷ AU$538m (Based on the trailing twelve months to December 2024). The 'return' refers to a company's earnings over the last year. Another way to think of that is that for every A$1 worth of equity, the company was able to earn A$0.17 in profit. View our latest analysis for Redox We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features. At first glance, Redox seems to have a decent ROE. On comparing with the average industry ROE of 11% the company's ROE looks pretty remarkable. Probably as a result of this, Redox was able to see a decent growth of 14% over the last five years. As a next step, we compared Redox's net income growth with the industry and were disappointed to see that the company's growth is lower than the industry average growth of 28% in the same period. Earnings growth is an important metric to consider when valuing a stock. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. By doing so, they will have an idea if the stock is headed into clear blue waters or if swampy waters await. If you're wondering about Redox's's valuation, check out this gauge of its price-to-earnings ratio, as compared to its industry. The really high three-year median payout ratio of 11,109% for Redox suggests that the company is paying its shareholders more than what it is earning. Still the company's earnings have grown respectably. Although, the high payout ratio is certainly something we would keep an eye on if the company is not able to keep up its growth, or if business deteriorates. While Redox has seen growth in its earnings, it only recently started to pay a dividend. It is most likely that the company decided to impress new and existing shareholders with a dividend. Our latest analyst data shows that the future payout ratio of the company is expected to drop to 79% over the next three years. Despite the lower expected payout ratio, the company's ROE is not expected to change by much. On the whole, we do feel that Redox has some positive attributes. As noted earlier, its earnings growth has been quite decent, and the high ROE does contribute to that growth. Still, the company invests little to almost none of its profits. This could potentially reduce the odds that the company continues to see the same level of growth in the future. The latest industry analyst forecasts show that the company is expected to maintain its current growth rate. Are these analysts expectations based on the broad expectations for the industry, or on the company's fundamentals? Click here to be taken to our analyst's forecasts page for the company. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
22-02-2025
- Business
- Yahoo
Redox (ASX:RDX) Is Due To Pay A Dividend Of A$0.06
Redox Limited's (ASX:RDX) investors are due to receive a payment of A$0.06 per share on 25th of March. Based on this payment, the dividend yield on the company's stock will be 4.0%, which is an attractive boost to shareholder returns. View our latest analysis for Redox While it is great to have a strong dividend yield, we should also consider whether the payment is sustainable. Prior to this announcement, Redox's dividend was making up a very large proportion of earnings and perhaps more concerning was that it was 159% of cash flows. This is certainly a risk factor, as reduced cash flows could force the company to pay a lower dividend. Over the next year, EPS is forecast to expand by 24.2%. Assuming the dividend continues along recent trends, we think the payout ratio could be 33% by next year, which is in a pretty sustainable range. The company hasn't been paying a dividend for very long at all, so we can't really make a judgement on how stable the dividend has been. This doesn't mean that the company can't pay a good dividend, but just that we want to wait until it can prove itself. Investors could be attracted to the stock based on the quality of its payment history. Let's not jump to conclusions as things might not be as good as they appear on the surface. Redox's earnings per share has shrunk at 59% a year over the past five years. Such rapid declines definitely have the potential to constrain dividend payments if the trend continues into the future. However, the next year is actually looking up, with earnings set to rise. We would just wait until it becomes a pattern before getting too excited. Overall, we don't think this company makes a great dividend stock, even though the dividend wasn't cut this year. With cash flows lacking, it is difficult to see how the company can sustain a dividend payment. We would probably look elsewhere for an income investment. Investors generally tend to favour companies with a consistent, stable dividend policy as opposed to those operating an irregular one. Meanwhile, despite the importance of dividend payments, they are not the only factors our readers should know when assessing a company. Taking the debate a bit further, we've identified 1 warning sign for Redox that investors need to be conscious of moving forward. Is Redox not quite the opportunity you were looking for? Why not check out our selection of top dividend stocks. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
